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(Auto)immune mediated diseases are diverse and may affect almost any organ. In the past their treatment has been largely with non-specific immunosuppression and supported, in controlling pain, with analgesics and nonsteroidal anti-inflammatory agents in, for example, rheumatoid arthritis. The side effects of immunosuppression with steroids and cytotoxic agents, which for any control of disease have to be taken on a long term basis, often outweigh the benefits of any treatment. However, over the past two decades the discovery of more specific immunosuppressive agents -for example, cyclosporin A (CsA), and the further understanding of underlying immune processes (for example, T cell activation, T cell receptors, cytokines) has led to a wave of interest in developing specific treatments for immune mediated diseases. Newer immunosuppressive therapies are aiming to give long term suppression of (auto)immune responses with only short term treatment and specificity for the desired antigen.
Endogenous posterior uveoretinitis (EPU) is one of the best ocular examples of putative (auto)immune disease. However, there is still conflict as to what constitutes EPU. EPU is characterised by a combination of discrete clinical signs which include vitreal infiltration with inflammatory cells (vitritis), focal or diffuse chorioretinal infiltration with leucocytes (choroiditis), inner and outer retinal vessel inflammation (retinal vasculitis), and macular and optic nerve head oedema. 1 2 From these building blocks of signs arises a large spectrum of clinical conditions including sympathetic ophthalmia, intermediate uveitis, birdshot chorioretinitis, and pigment epithelitis. Although these conditions vary in their presentation, degree of HLA association, and response to relatively non-specific treatment, there is growing evidence both clinically and in experimental models that these conditions are characterised by an exaggerated immune response which causes tissue destruction and, without an obvious infective aetiology, is likely to be autoimmune in nature (Table 1) .3 4 The immune mechanisms generated are either directed towards autoantigens or as a response triggered, for example, by an infectious agent (that is, foreign antigen), which may show some homology with host antigens and generate cross reactivity (molecular mimicry). The points at which the inflammatory response may be inhibited successfully would depend on whether the immune response was directed against host or foreign antigen which enters the tissue. Either way, when no overt infectious or neoplastic aetiology is found treatment may be directed towards dampening the resulting inflammatory cascade and hopefully reduce tissue damage. With the former I will discuss the possibility of inhibiting specific autoreactive T cells as opposed to inhibiting inflammatory mediators (cytokines) which result as a consequence of a pathogenic immune response.
Although present treatment is successful in some cases of EPU, as well as other autoimmune conditions, it is restricted by the required long term use, resistance in some patients, and significant side effects. Therefore there is a strong need for more selective and specific immunotherapy which is rapidly being developed and is now Targeting the TCR There are various approaches to attacking the TCR. They include directing monoclonal antibodies against TCR or its specific subunits (VP T cell specific depletion), TCR antagonism with antigen analogues, and activation of regulatory T cells via anti-idiotypic control of pathogenic T cell responses. These approaches are already being studied, and focus on the development of T cell receptor antagonists. Antagonists are analogues of MHC class II antigen/peptide which antagonises TCR preventing T cell activation. This proposal has yet to be tested in the animal model. I have also mentioned that there is restricted expression of TCR by autoreactive T cells. Certainly in animal models suppression of autoimmune disease can be produced by monoclonal antibody administration against specific regions of the TCR,25 26 but antibodies against more than one region of the TCR are often required to prevent disease successfully. In human as well as animal models of autoimmune disease there is some evidence of TCR restricted expression,27 28 but overall autoreactive T cells appear to be heterogeneous, which may make selective suppression difficult to achieve -that is, clinical success will only be possible if common TCR V genes are used by pathogenic T cells in different patients. This may also be the main problem preventing other approaches to inhibitions of TCR activation -for example, enhancing the anti-idiotypic T cell response which will inhibit the pathogenic activity of T cells. This approach is possible by administering peptides corresponding to T cell receptor sequences used by autoreactive T cells, the aim being to enhance regulatory T cells which are suppressive by their anti-idiotypic activity. The TCR is associated intimately with subunits of CD3, which is integral for activation of T cells. Monoclonal anti-CD3 antibodies will inhibit T cell activation, but this is relatively non-specific. 31 Other models of autoimmune disease have been used to study the role of other accessory moleculesfor example, CD40 and gp39 (the ligand for CD40, which is expressed on activated CD4 + cells) and it has been found that autoimmune disease can be inhibited by antigp39 antibody.32 With the increasing understanding of the immunological importance of these accessory molecule interactions, inhibition of these interactions suppressing T cell activation opens another avenue which may have therapeutic potential in the treatment of autoimmune disease, but again it is unlikely to be specific to autoreactive T cells.
Targeting the CD4 molecule There has recently been much progress in re-establishing tolerance to autoantigens (self antigens) in a sensitised immune system by directing antibodies against CD4 or CD8. In EAU administration of anti-CD4 antibody prevents the autoimmune disease.33 In transplantation models T cell tolerance can be maintained by combining antibodies which deplete CD4 and CD8 as well as block CD4 and CD8.34 In this model it was noted that tolerance was 'infectious' -that is, tolerant T cells were able to induce tolerance in potentially autoreactive naive T cells, the mechanism of which is unknown but may be the unmasking of regulatory T cells which protect against further autoimmune attack (for review see Waldmann and Cobold35). In the clinical setting, Campath-1H (humanised anti-CDw52 monoclonal antibody), which is directed against an antigen on all lymphocytes and some natural killer (NK) cells, has been used to treat a number of autoimmune conditions including rheumatoid arthritis,36 although it must be noted that not all patients respond. In some patients short term treatment does provide long term remission although in other patients this requires the additional treatment with anti-CD4 monoclonal antibody. In cases of systemic vasculitis a combination of anti-CD4 and Campath-1H has resulted in long term remissions.37 Campath-1H has also been successful in the suppression of EPU although we are still awaiting long term results (manuscript in preparation). Anti-CD4+ antibody treatment with humanised monoclonal antibodies has also been used in clinical trials of rheumatoid arthritis.38 There appears to be about a 50-60% response rate and treatment caused only a small drop in CD4+ levels; therefore its effect is unlikely to be depletion, as with anti-CDw52 treatment, but to be some tolerance inducing mechanism such as anergising (inactivating) the CD4+ T cell. Inhibition of the cytokine network has been the focus of recent developments of immunotherapy in animal models, the success of which has resulted in the onset of clinical trials in autoimmune diseases. This is mainly because the cytokines which activated CD4+ cells produce play a central role in the induction and perpetuation (and control) of an autoimmune response. Based on murine experimental models it is now thought that in humans CD4+ cells can also be characterised by their cytokine secretion profile into ThO, Thl, and Th2.54 Thi cells secrete IFN-y and also tumour necrosis factor (TNF-a), which activate macrophages enhancing antigen presentation, phagocytosis, and both superoxide and nitric oxide production; they also mediate delayed type hypersensitivity reactions,55 one of the hallmarks of EPU.
Activation of naive T cells also leads to synthesis of IL-2 and upregulation of IL-2 receptors on the cell surface which in turn stimulates further T cells activation and T cell proliferation. The interaction between cytokines and subsets of CD4+ cells is complex; however, it is slowly becoming unravelled. In brief, it is known that Th2 cytokines, IL-4 and IL-1O, inhibit the function ofThl cells and their cytokine secretion, particularly IL-1, TNF-a, IL-6, and IFN-y, and therefore interaction between these two 62 and indeed in these circumstances it may even be protective. However, this model has distinct pathogenic differences from retinal antigen-induced EAU, being mainly mediated by neutrophils and thus has a different immune activation and immunoregulatory cytokine profile. However, the point of this paradoxical effect emphasises the need for adequate knowledge of the effects and underlying immunobiology of immunoregulation by cytokines in animal models of (auto)immune disease before entering into clinical trials. IFN-y was used to treat MS and, rather than reducing inflammation, it induced MHC class II expression and made the disease worse, although interestingly and without explanation IFN-1 reduces the incidence of recurrences of MS, as documented by serial magnetic resonance imaging (for review see Ebers63). Similarly, in EAU, IFN--y upregulates MHC class II expression on resident cells64 and it is the blocking of such functions that will probably have a profound effect on the immunoregulation of autoimmune disease, such as EPU. There are also paradoxical effects of other cytokines.65 66 I have already mentioned TNF and a similar inflammatory mediator, IL-1, which is involved in the pathogenesis of many diseases. For example it is uveitogenic but is also able to inhibit other models of autoimmune diseases.67 There are now trials treating rheumatoid arthritis with recombinant IL-1 receptor (IL-i Ra)68 and a fusion protein of the IL-1R. 69 In both studies treatment was shown to be beneficial but only in some clinical variables. The treatment was noted to have only minor adverse effects, which may be expected as both IL-lRa and soluble IL-1R are naturally occurring molecules.
ACAID (anterior chamber associated immune deviation) is a phenomenon where an altered immune response is generated by placing antigen directly into the anterior chamber. 70 The anterior chamber is thought to be immunosuppressive mediated via certain cytokines such as transforming growth factor a (TGF-P), a small secreted polypeptide which has suppressive actions on T cells.7' In EAE, there also appears to be a suppressive effect of TGF-1 even in the presence of IFN-y.72 TGF-1 mediated suppression has the advantage of not being restricted by antigen specificity. TGF-1 is both suppressive and proinflammatory. As is seen in the ACAID model TGF-1 in the aqueous seems to be important for the maintenance of an immunosuppressive environment. Although also associated with fibrosis in wound healing, it may be of benefit in promoting healing -for example, in full thickness macular holes. TGF-P, therefore, does have differential effects which appear to depend on cell type, state of immune activation, and site which may limit its clinical efficacy.65 66 Inhibiting effector cells I have already discussed the possibilities of targeting cells responsible for mediating inflammatory response in autoimmune disease, including CD4+ and CD8+ cells. Macrophages are also directly involved in the pathogenesis of CD4 + (Thi) mediated diseases such as EAE and EAU. In EAE selectively depleting macrophages with a specific drug (dichloromethyl ketone) encapsulated in a mannosylated liposome (being able to cross the blood-brain barrier) can inhibit EAE. 73 Before the effector response can occur the cells obviously have to enter the target organ, a complex process which involves not only changes in the blood-retinal or blood-brain barrier74 but adhesion of activated cells to endothelium. Cell adhesion is a multistep process which involves the initial attachment of cell to vessel wall endothelium by selectins, such as E-selectin, which in turn activates integrins on leucocytes (as a result of the cellular conformational changes that have occurred), such as leucocyte functional antigen 1 (LFA-1). These bind to endothelial adhesion molecules like intercellular adhesion molecule 1 (ICAM-1). Expression of these molecules has been demonstrated in chronic intraocular inflammation.75
One method, therefore, of suppressing the immune response is by targeting the adhesion process via monoclonal antibodies directed towards adhesion molecules expressed on circulating activated cells such as ICAM-1 and LFA-1. Suppression of EAU occurs with monoclonal antibodies directed against these cell surface adhesion molecules. However, these molecules are also important for cell-cell interaction during cell activation and therefore their effect in suppressing EAU may be secondary to inhibition of cell activation, rather than inhibition of homing.
There are many potential applications of targeting cytokines, especially with the advancement of recombinant technology and development of humanised antibodies for clinical use and the understanding of the immunobiology of the cytokine network in immune mediated diseases. Focusing on TNF-cx had already been shown to be successful and treatments, as I have mentioned, may be improved when it is used in combination -for example, targeting both CD4+ T cells and cytokines. Overall we are entering a very exciting generation of new, more specific immunotherapies which will directly affect our future attractive forms of treatment but the problem is which is the best approach and by which route inducing tolerance will suppress the inflammatory response and as a result redress the immunoregulatory balance (Fig 3) ? 84 which appears to be antigen specific. Mucosal tolerance induction in models of autoimmune disease appears to be driven by the generation of suppressor CD8 + cells, although in collagen induced arthritis it has been suggested that oral tolerance generates active peripheral suppression via both CD8+ and CD4+ cells driven through the action of their regulatory cytokines, particularly IL-4, IL-10, and TGF-,3.
Interestingly, in the immature neonatal system oral administration of antigen in tolerogenic doses enhances immune mediated diseases such as EAE when the animal is adult,85 which suggests that when antigen is presented to the immature mucosal lymphoid system (capable of generating, like the thymus, its own maturing T cells) it may contribute towards the pathogenesis of autoimmune disease later in life. We obviously have a delicate balance between possible exacerbation of (auto)immune disease and suppression when antigens are administered via mucosal lymphoid tissue, which is perhaps dependent upon previous exposure. Although in experimental models mucosal tolerance can prevent disease onset, it must be established that the inflammatory response is not exacerbated by this mode of treatment. In EAU, active disease is suppressed with nasal administration of antigen but there is still target organ infiltration (that is, rod outer segment leucocytic infiltration) which does not occur when tolerogenic doses of antigen are given before immunisation. 86 In EAE, chronic relapsing disease may be suppressed by myelin basic protein feeding.87 A full appraisal of whether mucosal tolerance therapy suppresses ongoing active disease is required before clinical trials can commence in uveitis. It may be that co-therapy with specific CD4+ monoclonal antibodies which would induce a period of immunosuppression could increase the efficacy of tolerance induction, so that once the cellular balance was redressed, continued mucosal tolerance therapy would maintain the antigen specific suppression and control any further exacerbations of disease. However, another problem with mucosal tolerance therapy is the unconfirmed evidence that the antigens which produce animal models of autoimmunity are important in humans. In some models like EAU, the circumstantial evidence is strong for S-Ag and IRBP to be more than just the putative autoantigens in human disease. It is possible that mucosal tolerance does initiate an effect by stimulating bystander suppression which may, in turn, be mediated by TGF-1, so that the lack of known autoantigens or the antigenspecific nature of the therapy may not be a drawback to clinical use. Despite these potential problems a clinical trial has begun by feeding of bovine myelin to patients with chronic relapsing MS. 88 Provisional results have been published after a year of oral feeding of protein to patients, and although the efficacy of this form of treatment has not been shown, tolerance therapy was without any adverse effects, and the initial results indicated less exacerbation of MS in the treated group (relapse was documented in 6/15 patients in the treated group compared with 12/15 in control group). The potential of this form of suppression by induction of mucosal tolerance has been demonstrated recently by the topical administration of retinal antigens into the conjunctival sac which suppresses EAU in an antigen specific manner, and is thought to be mediated via the conjunctival associated lymphoid tissue (CALT).89 By whatever mechanisms tolerance is induced this form of therapy promises exciting developments in the treatment of autoimmune disease.
The future I have focused on many experimental methods which successfully suppress or abolish immune responses in models of autoimmune disease. Much of the work only supports suppression of the primary response and prevention of the disease, which is largely because many of these models are not chronic and relapsing in nature; only recently are data concerning suppression of active disease (more pertinent to situation in humans) becoming available. At present, however, even with the advent of CsA therapy in autoimmune disease, we are still restricted by unacceptable side effects, a high incidence of resistance to therapy, and relapses which occur despite continued immunosuppression. The objectives of newer specific immunotherapies are to suppress the immune response for longer and with an acceptable risk/benefit ratio. The most specific treatments, such as inhibiting TCR/MHC/peptide binding, are still in their infancy and may be hampered in the future by the broad T cell repertoire which is apparent in autoimmune disease and the variety of autoantigens to which individual patients are sensitised. More encouraging are the developments of inhibiting the effector mechanisms via targeting CD4+ T cells, cytokines, or inducing tolerance via presentation of antigen to the mucosal system. All these methods are now entering the era of clinical trials. And already, in the limited pilot studies which are being performed, they are showing promise in the treatment of autoimmune diseases such as uveitis, psoriasis, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory bowel diseases.
